Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAR3419 · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| SAR3419 | EXPERIMENTAL | All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation |
| SAR3419 + Rituximab | EXPERIMENTAL | Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent. |
| Name | Type | Description |
|---|---|---|
| SAR3419 | DRUG | Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous |
| rituximab | DRUG | Pharmaceutical form:solution for infusion Route of administration: intravenous |
Inclusion criteria: * Histological diagnosis of Diffuse Large B Cell Lymphoma (de novo or transformed) expressing CD19 by immunohistochemistry or flow cytometry analysis (\>30% positivity), based on recent (less than 6 months) or new biopsy. * At least 1 prior specific therapeutic regimen, one of w...
SAR3419 is an investigational oncology drug being studied for the treatment of B-cell non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma (DLBCL). It has been evaluated in clinical trials for patients with relapsed or refractory disease, both as a single agent and in combination with rituximab.
SAR3419 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi has sponsored clinical trials of SAR3419 in patients with B-cell lymphomas, including diffuse large B-cell lymphoma.
SAR3419 has completed Phase 2 clinical trials for the treatment of diffuse large B-cell lymphoma. It is an investigational drug that has not been approved by regulatory authorities, and it remains in clinical development. The completed trials include both Phase 1 and Phase 2 studies.
SAR3419 has been studied in four completed clinical trials. These include NCT00549185 and NCT00796731, both Phase 1 studies in relapsed/refractory B-cell non-Hodgkin's lymphoma, and NCT01470456 and NCT01472887, both Phase 2 studies in relapsed/refractory diffuse large B-cell lymphoma.
SAR3419 is a small molecule drug that targets CD19, a protein expressed on B-cells. By binding to CD19, SAR3419 is designed to deliver a cytotoxic payload to malignant B-cells, potentially leading to their death. This mechanism is being investigated for the treatment of B-cell lymphomas.
SAR3419 is a unique investigational drug and is not known to be the same as any other approved medication. It is a small molecule that targets CD19, and it has been studied under its own name in clinical trials for B-cell lymphomas.